Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib + Idelalisib +/- Obinutuzumab in R/R CLL
NCT02968563Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirabrutinib in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Rate of Complete Response/Complete Remission at Week 25. Started Dec 2016; status: completed.
02
Drugs
tirabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02968563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968563.